Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn - LARVOL DELTA

TASTE-SVD: Treatment of Acute Ischemic Stroke with Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital | Initiation date: Mar 2025 ➔ Jun 2025

Trial initiation date • Alzheimer's Disease • Cardiovascular • Ischemic stroke

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Simcere Pharmaceutical Co., Ltd | N=80 ➔ 200 | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment change • Trial completion date • Trial primary completion date • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Ischemic stroke

TASTE-SVD: Treatment of Acute Ischemic Stroke With Sublingual Edaravone Dexborneol in Small Vessel Disease (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital

New P3 trial • Cardiovascular • Ischemic stroke

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Simcere Pharmaceutical Co., Ltd | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Ischemic stroke

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Simcere Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Ischemic stroke

EDARAVONE DEXBORNEOL IN TREATMENT OF LARGE ARTERY ATHEROSCLEROSIS STROKE (ESOC 2024) - "This analysis demonstrated that both injectional and sublingual edaravone dexborneol showed more favorable functional outcomes without increase in AEs in LAA stroke."

Atherosclerosis • Cardiovascular • Dyslipidemia • Ischemic stroke

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Simcere Pharmaceutical Co., Ltd

New P2 trial • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Ischemic stroke

Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. (PubMed, JAMA Neurol) - P3 | "Among patients with AIS within 48 hours, sublingual edaravone dexborneol could improve the proportion of those achieving a favorable functional outcome at 90 days compared with placebo. ClinicalTrials.gov Identifier: NCT04950920."

Clinical • Journal • Cardiovascular • Ischemic stroke

Longitudinal evaluation of major salivary gland functioning in Sjögren's disease patients in a prospective standard-of-care cohort. (PubMed, Clin Exp Rheumatol) - "Overall, major salivary gland functioning assessed with SGUS, sialometry and PROMs did not change significantly up to 5 years of follow-up in a standard-of-care cohort of SjD patients from daily clinical practice."

Journal • Dental Disorders • Immunology • Sjogren's Syndrome • Xerostomia

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Simcere Pharmaceutical Co., Ltd | Not yet recruiting ➔ Completed

Trial completion

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Simcere Pharmaceutical Co., Ltd

New P1 trial

Efficacy and safety of Y-2 sublingual tablet for patients with acute ischaemic stroke: protocol of a phase III randomised double-blind placebo-controlled multicentre trial. (PubMed, Stroke Vasc Neurol) - P3 | "This trial will provide valuable evidence for the efficacy and safety of Y-2 sublingual table for improving 90 days the functional outcomes in patients with AIS."

Journal • P3 data • Cardiovascular • Ischemic stroke